Novartis, a drug company, has recently released its quarterly report on earnings and the future looks bright. This can be in part thanks to the recent approval for FTY720, a drug that combats multiple sclerosis. The company reports earnings of “free cash flow” at about $2.4 million dollars.
Multiple Sclerosis (MS) is, according to WebMd, “is a disease that affects the brain and spinal cord resulting in loss of muscle control,vision, balance, and sensation (such as numbness). With MS, the nerves of the brain and spinal cord are damaged by one’s own immune system.” One of the most insidious parts of this disease is that the symptoms come and go. Sometimes a person can’t walk. Then the next day, they can walk but cannot see.
While there have been many improvements in the treatment of MS, it remains incurable at this time. Patients can compare various treatment options, including medication and physical therapy, to see what will work best with them by clicking here http://www.webmd.com/relapsing-ms/consider-treatment
*
*
***********************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
(This will take 20-25 seconds and will empower you
with informaton and learning)
Thank you for allowing me to help to keep you informed
****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews